Puma Biotechnology reports Q4 EPS 26c vs. 39c last year

Reports Q4 revenue $75.5M vs. $59.1M last year. “Our financial performance in the fourth quarter and full year 2025 demonstrates continued momentum, with net income marking our third consecutive year of profitability, a testament to our disciplined execution and careful fiscal stewardship,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. “Our current guidance forecasts that we will continue to be profitable in 2026, which we believe is a result of this continued financial discipline. In parallel, we continue to advance alisertib clinically through ALISCA(TM)-Breast1 and ALISCA(TM)-Lung1, targeting patient populations in chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer and extensive-stage small cell lung cancer.”